Losartan Potassium Tablet, Film Coated
Product Images NDC 71335-1221

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71335-1221). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351221)

Losartan Potassium 50 mg tablet label by Bryant Ranch Prepack. The label includes the drug name, strength, dosage form, and a comparison to Cozaar 50 mg tablet by Aurobindo Pharma Limited. It specifies a package size of 30 tablets, shows storage instructions at 20°-25°C, and includes a barcode and lot number 152348. The label also cautions to keep all drugs out of reach of children.*

FDA Label Image

Figure1 (Losartan Fig1)

A line graph comparing the percentage of patients with the primary endpoint over time between Losartan Potassium and Atenolol. The x-axis represents study months up to 66 months, and the y-axis shows the percentage of patients (0 to 16%). The graph includes a note on adjusted risk reduction of 13% with p=0.021, indicating statistical significance.*

FDA Label Image

Figure2 (Losartan Fig2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months between Atenolol and Losartan Potassium. The graph shows adjusted risk reduction data, with Losartan Potassium represented by a solid line and Atenolol by a dotted line, indicating a 25% adjusted risk reduction with statistical significance (p=0.001).*

FDA Label Image

Figure 3 (Losartan Fig3)

Figure 3 presents a forest plot showing primary endpoint events within demographic subgroups comparing Losartan Potassium and Atenolol. Subgroups include age, gender, race, ischemic heart disease, diabetes, and cardiovascular disease history. The graph displays event rates and hazard ratios with confidence intervals for primary composite outcomes and fatal/non-fatal stroke, indicating relative favorability between Losartan Potassium and Atenolol.*

FDA Label Image

Figure-4 (Losartan Fig4)

A line graph comparing the percentage of patients with events over 48 months between Losartan Potassium and placebo groups. The graph shows cumulative event rates with Losartan Potassium having lower percentages than placebo, indicating risk reduction noted as 16.1% with a p-value of 0.022.*

FDA Label Image

Chemical Structure (Losartan Str)

Chemical structure diagram of Losartan Potassium, illustrating its molecular arrangement including rings, chains, and potassium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.